Skip to main content
Top
Published in: Netherlands Heart Journal 11/2017

Open Access 01-11-2017 | Original article

In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment

Authors: N. van Boven, K. M. Akkerhuis, S. S. Anroedh, L. C. Battes, K. Caliskan, W. Yassi, O. C. Manintveld, J. H. Cornel, A. A. Constantinescu, H. Boersma, V. A. Umans, I. Kardys

Published in: Netherlands Heart Journal | Issue 11/2017

Login to get access

Abstract

Introduction

Blood biomarkers have the potential to monitor the severity of chronic heart failure (CHF). Studies correlating repeated measurements of blood biomarkers with repeatedly assessed New York Heart Association (NYHA) class over a prolonged follow-up period, and concomitantly investigating their associations with clinical endpoints, have not yet been performed.

Methods

Between 2011–2013, 263 CHF patients were included. At inclusion and subsequently every 3 months, we measured N‑terminal pro-B-type natriuretic (NT-proBNP), high-sensitivity troponin T (Hs-TnT) and C‑reactive protein (CRP), and assessed NYHA class. The primary endpoint comprised heart failure hospitalisation, cardiovascular mortality, cardiac transplantation or left ventricular assist device implantation. Time-dependent Cox models were used.

Results

Mean age was 67 ± 13 years, 72% were men and 27% were in NYHA class III–IV. We obtained 886 repeated measures (median 3 [IQR 2–5] per patient). The primary endpoint was reached in 41 patients during a median follow-up of 1.0 [0.6–1.4] year. Repeatedly measured NT-proBNP and Hs-TnT were significantly associated with repeatedly assessed NYHA class, whereas CRP was not (NT-proBNP: β [95% CI]: 1.56 [1.17–2.06]ln(ng/l) increase per point increase in NYHA class, p = 0.002; HsTNT: β [95% CI]: 1.58 [1.21–2.07]). Serially measured NT-proBNP (HR [95% CI]:2.86 [1.73–4.73]), CRP (1.69 [1.21–2.34]) and NYHA class (2.33 [1.51–3.62]) were positively and independently associated with the primary endpoint, whereas Hs-TnT lost statistical significance after multivariable adjustment. A model containing serially measured NYHA class and NT-proBNP displayed a C-index of 0.84, while serially measured NYHA class and CRP showed a C-index of 0.82.

Conclusion

Temporal NT-proBNP, CRP and NYHA class patterns are independently associated with adverse clinical outcome. Serially measured NT-proBNP and NYHA class are best suited for monitoring CHF outpatients.
Appendix
Available only for authorised users
Literature
1.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMed
3.
go back to reference Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e327.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e327.CrossRefPubMed
4.
go back to reference Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442. https://doi.org/10.1093/eurheartj/ehn309.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442. https://​doi.​org/​10.​1093/​eurheartj/​ehn309.CrossRefPubMed
6.
go back to reference de Couto G, Ouzounian M, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 2010;7:334–44.CrossRefPubMed de Couto G, Ouzounian M, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 2010;7:334–44.CrossRefPubMed
7.
go back to reference Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422–30.CrossRefPubMed Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422–30.CrossRefPubMed
8.
go back to reference Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLOS ONE. 2013;8:e58287.CrossRefPubMedPubMedCentral Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLOS ONE. 2013;8:e58287.CrossRefPubMedPubMedCentral
9.
go back to reference Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B‑type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–14.CrossRefPubMed Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B‑type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–14.CrossRefPubMed
10.
go back to reference Anand IS, Latini R, Florea VG, et al. C‑reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–34.CrossRefPubMed Anand IS, Latini R, Florea VG, et al. C‑reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–34.CrossRefPubMed
11.
go back to reference Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249–57.CrossRefPubMed Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249–57.CrossRefPubMed
12.
go back to reference Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B‑type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35:1559–67.CrossRefPubMedPubMedCentral Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B‑type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35:1559–67.CrossRefPubMedPubMedCentral
13.
go back to reference Yan RT, White M, Yan AT, et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol. 2005;96:698–704.CrossRefPubMed Yan RT, White M, Yan AT, et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol. 2005;96:698–704.CrossRefPubMed
14.
go back to reference Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N‑terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can pro-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56:2090–100. https://doi.org/10.1016/j.jacc.2010.07.030.CrossRefPubMed Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N‑terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can pro-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56:2090–100. https://​doi.​org/​10.​1016/​j.​jacc.​2010.​07.​030.CrossRefPubMed
15.
go back to reference Troughton R, Michael FG, Januzzi JL Jr.. Natriuretic peptide-guided heart failure management. Eur Heart J. 2014;35:16–24.CrossRefPubMed Troughton R, Michael FG, Januzzi JL Jr.. Natriuretic peptide-guided heart failure management. Eur Heart J. 2014;35:16–24.CrossRefPubMed
17.
go back to reference Luther SA, McCullough PA, Havranek EP, et al. The relationship between B‑type natriuretic peptide and health status in patients with heart failure. J Card Fail. 2005;11:414–21.CrossRefPubMed Luther SA, McCullough PA, Havranek EP, et al. The relationship between B‑type natriuretic peptide and health status in patients with heart failure. J Card Fail. 2005;11:414–21.CrossRefPubMed
18.
go back to reference Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707–15.CrossRefPubMed Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707–15.CrossRefPubMed
19.
go back to reference Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.CrossRefPubMed Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.CrossRefPubMed
21.
go back to reference Rizopoulos D, Takkenberg JJ. Tools & techniques—statistics: dealing with time-varying covariates in survival analysis—joint models versus Cox models. EuroIntervention. 2014;10:285–8.CrossRefPubMed Rizopoulos D, Takkenberg JJ. Tools & techniques—statistics: dealing with time-varying covariates in survival analysis—joint models versus Cox models. EuroIntervention. 2014;10:285–8.CrossRefPubMed
Metadata
Title
In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment
Authors
N. van Boven
K. M. Akkerhuis
S. S. Anroedh
L. C. Battes
K. Caliskan
W. Yassi
O. C. Manintveld
J. H. Cornel
A. A. Constantinescu
H. Boersma
V. A. Umans
I. Kardys
Publication date
01-11-2017
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 11/2017
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-017-1040-x

Other articles of this Issue 11/2017

Netherlands Heart Journal 11/2017 Go to the issue